We often struggle with postural hypotension in our #amyloid patients. Dr. Carroll gives us clinical pearls #ISA_2024
Why do we worry about supine HTN? —> can worsen nocturnal diuresis and⬇️ daytime BP
🔑 Keep head up during sleep
🔑 Eat prior to bed
🔑 No meds 4 hrs prior to 🛌

Turbulences✈️& heart attacks - am I at risk?

Discover if air travel is safe for those with🫀conditions, potential causes of in-flight heart issues & preventive tips in this 8world News 8视界新闻网 interview with Prof Tan Huay Cheem, Senior Advisor, #NUHCS .

Watch: youtube.com/watch?v=v9JbYx…

‼️ don’t miss the first meeting on location from Young@Heart 💛
📅 Wednesday June 5th
⏰ 11:00-13:00h
📍 UMCG
More information and registration ⬇️
UMCG Cardiology Research Institute Peter-Paul Zwetsloot Anke Smits Iris Beldhuis Marlene Vijver Kevin Damman Nils Bömer Peter van der Meer Adriaan Voors

📣 Register NOW for the First #HFAJournalClub 📰

The PUSH-AHF Trial
🗓️ 5 June 2024
🕖 18:00 CET
📩 SEND YOUR QUESTIONS before the event

Made by and for the #HFA_Young

🔗esc365.escardio.org/event/1635

#HFA_ESC European Society of Cardiology #HFA_Young

Jozine ter Maaten Chris Kapelios Henrike Arfsten Antonio Cannata'

Tune in JACC Journals #JACCAdvancesPulse for valuable insights from Erin D. Michos, M.D. & ambarish on
🎯 Role of #Cardiometablic multispecialty clinics in current #CVD landscape

🎧👉 jacc.org/jacc-advances/…
Candice Silversides Sadeer Al-Kindi, MD Bailey Ann Estes Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 American College of Cardiology

Safety of #daratumumab monotherapy in newly diagnosed Stage 3b #AL presented by Prof. Efstathios Kastritis #ANDROMEDA excluded Mayo Stage 3b patients. #ISA_2024 University of Athens The International Society Of Amyloidosis
📍6 month OS rate = 65%
📍>50% achieved VGPR
📍27.5% had cardiac response at 6 months

Trial after trial, and with safer stent platforms, dual antiplatelet therapy (DAPT) durations are decreasing. But are we ready to eliminate DAPT entirely? We wrote this viewpoint to summarize the evolutionary journey of trials on aspirin-free strategies after percutaneous

I am getting this question a lot, so I'll try to rephrase! Another way to think of it:

Comparison in the top panel is SGLT2i + GLP-1RA vs GLP-1RA alone (everyone on GLP-1RA)

Bottom is SGLT2i vs placebo (no-one on GLP-1RA)

Clear benefit of SGLT2i on top of GLP-1RA #ERA24

In an analysis of VICTORIA, Dr. Robert Mentz, MD shows #vericiguat does not reduce *total* HF hospitalization or CV death in #HFrEF . Mortality was high following HF hospitalization. bit.ly/3UYEL32

#JACCHF #HeartFailure #GDMT

The mortality rate in FLOW was the highest of any recent CKD outcome trials

And highlighting the potential for combination therapy to substantially improve outcomes

Independent commentary by Christoph Wanner

#era24 ERA - European Renal Association

New #ESCTVToday episode 🤗

Michael Boehm discusses the use of beta-blockers in patients after myocardial infarction. What are the key findings of the REDUCE-AMI trial and the most important implications for current clinical practice? bit.ly/4aAav4n

#CVD #MI #cardiology

Your one-stop hub for #amyloidosis and #CardioOnc is finally here! The #JACCCardioOnc Amyloidosis Hub is ready to inspire, inform, and invigorate with cutting-edge science and evidence-based care. bit.ly/3X1C6sh

The International Society Of Amyloidosis The Penn Thalheimer Center for Cardio-Oncology

Amazing is right.

I need to look at the data but we are at the point where it is hard to argue against first line therapy for DM being anything other than the combination of SGLT2 + GLP1-RA.

🚨 Just published! Our editorial on enhancing machine learning (ML) in risk prediction for cardiovascular (CV) medicine is out! 🌟
Dive into this integrative (yes, a bit complex) look at how ML can improve CV risk prediction.📚💡
Let’s explore! 📊🧠 sciencedirect.com/science/articl…
🤖

🫁On VA #ECMO cardiogenic pulmonary edema & atelectasis may exacerbate RV dysfunction (⬆️lung elastance/RV afterload). Here report of RV PV loops use during decremental PEEP trial to identify optimum level from cardio-respiratory viewpoint.
asaiojournal
🔓bit.ly/3UVuPat

FLOW : Effects of #Semaglutide on #CKD in Patients with #T2DM

📍24% ⬇️ risk of major kidney disease events vs. placebo (HR 0.76, 95% CI 0.66-0.88, P=0.0003) 🎯

📍18% ⬇️ in MACE (HR 0.82, 95% CI 0.68-0.98, P=0.029) 🎯

📍20% ⬇️ in all-cause ☠️ (HR 0.80, 95% CI 0.67-0.95, P=0.01)

Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the #HFA of the ESC

onlinelibrary.wiley.com/doi/full/10.10… #CardioEd
#EJHF European Society of Cardiology Journals EJHF Editor-in-Chief Amina Gianluigi Savarese Magdy Abdelhamid Ekaterini Lambrinou💙

In patients w #ChronicKidneyDisease &Type 2 #Diabetes :
#Semaglutide ⬇️ the primary outcome of kidney events, composite ESKD, >50% reduction in eGFR, or CV death by 24% vs placebo (331 vs. 410 events; HR 0.76; 95% CI, 0.66 to 0.88; P=0.0003.
#GLP1RA nejm.org/doi/full/10.10…

Amazing talk by Tariq Ahmad MD MPH !!! Some key slides that stuck with me... DeBakey CV Education - World Class CV Training #CardioX #CardioTwitter #HeartFailure #HFA_young
youtube.com/watch?v=QNdt0Q…

There’s more
underneath the surface
than meets the eye.
And it’s all
part of the #journey .